Sign In
Buy GBIO
$5.34
+0 (+0%)
At Close: May 05, 2026
Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates
06:41pm, Wednesday, 07'th May 2025
Generation Bio Co. (GBIO) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $1.12 per share a year ago.
Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results
04:05pm, Wednesday, 07'th May 2025
- Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA
Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference
06:59am, Wednesday, 02'nd Apr 2025
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune disease
Generation Bio Co. (GBIO) Reports Q4 Loss, Tops Revenue Estimates
06:15pm, Thursday, 13'th Mar 2025
Generation Bio Co. (GBIO) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.53 per share a year ago.
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
04:05pm, Thursday, 13'th Mar 2025
- Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases
Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference
06:59am, Monday, 24'th Feb 2025
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases
Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.
05:00am, Thursday, 06'th Feb 2025
MUNICH, Germany--(BUSINESS WIRE)--Tubulis today announced the appointment of Matthew Norkunas, MD, MBA, as Chief Financial Officer (CFO) and President of Tubulis Inc., further strengthening its manage
Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases
04:30pm, Monday, 06'th Jan 2025
CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company working to change what is possible for people living with T cell-driven autoimmune diseases
Generation Bio Co. (GBIO) Reports Q3 Loss, Tops Revenue Estimates
06:45pm, Wednesday, 06'th Nov 2024
Generation Bio Co. (GBIO) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.43 per share a year ago.
Generation Bio Announces the Presentation of Preclinical Data on ctLNP and iqDNA at the ESGCT 31st Annual Congress
06:59am, Tuesday, 22'nd Oct 2024
CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today pres
Generation Bio to Present at the 2024 Cantor Global Healthcare Conference
04:05pm, Thursday, 12'th Sep 2024
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced
Generation Bio Co. (GBIO) Reports Q2 Loss, Tops Revenue Estimates
08:36pm, Wednesday, 07'th Aug 2024
Generation Bio Co. (GBIO) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.47 per share a year ago.
Generation Bio to Present at the Canaccord Genuity 44th Annual Growth Conference
06:59am, Tuesday, 06'th Aug 2024
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce
Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit
06:59am, Friday, 14'th Jun 2024
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced
Cofi.ai Names Aaron Kizer President and Equity Partner
09:00am, Monday, 20'th May 2024
AUSTIN, TX/ ACCESSWIRE / May 20, 2024 / Cofi.ai, a groundbreaking financial planning and analysis software built for VC/PE and SMB tech companies, announced today that Aaron Kizer has joined the compa
